White Bear Lake, Minnesota — November 20, 2025 — Envoy Medical Inc. (NASDAQ: COCH) announced the issuance of U.S. Patent No. 12,465,754 by the United States Patent and Trademark Office on November 11 2025. The patent, titled “Combination Implant System with Removable Earplug Sensor and Implanted Battery,” covers a novel fully implanted cochlear implant system featuring a removable ear-plug sensor coupled with an implanted rechargeable battery and signal-processing subsystem, further solidifying the company’s leadership in next-generation hearing-implant innovation.
Science Significance
Scientifically, this granted patent introduces a transformative architecture in auditory prosthetics by integrating a removable earplug sensor that captures sound and transmits signals wirelessly to an implanted stimulation module powered by a rechargeable internal battery. This design promises enhanced sensor fidelity, minimized external hardware, and improved patient comfort compared with traditional external-processor cochlear systems. The system’s engineering potentially enables superior electromagnetic coupling, integrated signal processing and lowered surgical complexity—a significant advancement in the neuroprosthetics domain.
Regulatory Significance
Advertisement
From a regulatory standpoint, Envoy Medical’s strengthened intellectual-property portfolio supports progression toward future regulatory milestones including FDA submission and CE mark applications for its investigational Acclaim® Cochlear Implant system. The company already holds Breakthrough Device Designation from the FDA for Acclaim and is conducting pivotal-trial investigations in the U.S. The newly issued patent helps underpin CMC and design-control documentation, bolstering the company’s ability to meet regulatory expectations around device risk management, reliability/traceability and post-market surveillance for a fully implanted hearing system.
Business Significance
On the business front, the patent grant enhances Envoy’s competitive moat and supports its strategy to move beyond the currently marketed Esteem® Fully Implanted Active Middle Ear Implant. The new IP protects future product-line extensions, accessories and service platforms—strengthening the company’s value proposition for strategic partnerships, device-ecosystem licensing and long-term commercialisation. As the hearing-implant market evolves toward fully implanted, patient-friendly devices, Envoy’s patent may increase its market relevance, attract investor interest and drive new revenue opportunities.
Patients’ Significance
For patients with severe to profound sensorineural hearing loss, the advent of a fully implanted cochlear system featuring minimal external hardware could significantly improve quality of life by offering 24/7 hearing capability, fewer visible components, and lower maintenance burdens. The integrated ear-plug sensor and implanted module may improve usability, reduce stigma and increase device adoption in populations unwilling or unable to use external processors. By expanding the design scope of hearing-implant options, Envoy’s innovation holds potential to deliver better access, patient satisfaction and long-term outcomes.
Policy Significance
From a policy and public-health perspective, the development of next-generation cochlear implant technologies aligns with broader goals to reduce disability associated with hearing loss, enhance accessibility of implantable solutions and promote innovation in medical devices. Intellectual-property protection incentivises investment and supports a device-ecosystem that can deliver high-quality, regulated medical technology. The patent reaffirmation underlines the role of robust IP frameworks in driving medical-device advancement, ensuring competitive markets, and ultimately benefiting patient care and healthcare system efficiency.
In summary, Envoy Medical’s issuance of U.S. Patent 12,465,754 marks an important inflection point in cochlear-implant innovation, combining a removable earplug sensor and implanted battery into a fully implanted hearing system. This milestone strengthens the company’s scientific foundation, regulatory readiness, commercial positioning and potential patient impact. As Envoy advances its investigational Acclaim® device toward regulatory approval and commercial launch, this patent bolsters confidence in the company’s trajectory and underscores the continued evolution of implantable hearing-technologies.
Source: Envoy Medical press release
